Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hoth Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical issuer’s material events, capital structure actions, governance arrangements and listing compliance matters. Recent 8-K disclosures cover registered direct offerings of common stock, private-placement warrants, use of a Form S-3 shelf registration, and at-the-market offering prospectus supplements.
The filing record also includes Regulation FD and other-event disclosures for management presentation materials about the therapeutics pipeline and weight-loss drug program, executive employment agreement information, Nasdaq minimum bid price compliance notices, and the formation of Rocket One Inc., a wholly owned subsidiary formed to acquire, own and operate space-industry assets, including nano rocket systems for nanosatellite deployment.
Rocket One Inc. amends its prospectus supplement to increase the amount available under its at-the-market Sales Agreement with H.C. Wainwright & Co., LLC. The company is offering up to an additional $2,661,176 of common stock for sale under the Sales Agreement.
The amendment states the company previously sold 6,824,327 shares for gross proceeds of approximately $6.6 million under the Sales Agreement. It reports 21,022,498 shares outstanding, with 20,468,902 shares held by non-affiliates, and a public-float market value of $27,837,706 based on a $1.36 per-share closing price on May 27, 2026. The filing confirms eligibility under General Instruction I.B.6 of Form S-3 to sell up to the additional amount.
Rocket One Inc., formerly Hoth Therapeutics, has amended its Nevada charter to change its corporate name to Rocket One Inc. effective May 26, 2026. The company’s common stock will begin trading on The Nasdaq Capital Market under the new ticker “RKTO” on May 28, 2026, replacing “HOTH.”
The company is repositioning around the “orbital economy,” focusing on next-generation nanomagnetic AI chip technology designed for ultra-low-power, radiation-tolerant computing in space and defense applications. Its legacy biotechnology programs will continue under a wholly owned subsidiary, now named Rocket One.0 Inc. Shareholder rights and the CUSIP for the common stock remain unchanged.
Hoth Therapeutics has created a new subsidiary, Rocket One Inc., which entered into two exclusive license agreements with Virginia Commonwealth University Intellectual Property Foundation. These give Rocket One exclusive, royalty-bearing rights to certain AI semiconductor acceleration and spintronic computing patents and related technical information for commercial use in data centers and artificial intelligence.
The licenses run until the last licensed patent expires or 15 years from the first commercial sale of a covered product or service, whichever is later, and include tiered royalties on net sales, a percentage of sublicensing revenue, minimum annual payments, and reimbursement of patent costs. The company plans to change its name to Rocket One, Inc., pivot its main focus toward AI infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing, while exploring moving its biotechnology programs into a separate wholly owned subsidiary.
Hoth Therapeutics reported a quarterly net loss of approximately $2.7 million, improving from about $3.5 million a year earlier, with no product revenue. Research and development expenses were roughly $1.5 million and general and administrative costs about $1.1 million, both down year over year.
Cash and cash equivalents were $4.0 million as of March 31 2026 against an accumulated deficit of roughly $75.6 million, and management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional capital. During the quarter Hoth raised about $0.7 million via its at‑the‑market program and subsequently closed a separate equity and warrant financing with gross proceeds of about $2.0 million to help fund ongoing clinical programs.
Hoth Therapeutics, Inc. formed a new wholly-owned subsidiary, Rocket One Inc., by filing Articles of Incorporation in Nevada on April 22, 2026. Rocket One is intended to acquire, own and operate space-industry assets, including nano rocket systems used to deploy nanosatellites.
The company characterizes this as part of a potential expansion into the space industry and includes extensive cautionary language that these plans are forward-looking and subject to risks and uncertainties described in its prior SEC filings.
Hoth Therapeutics received a notice from Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1.00 per share, after trading below that level for 30 consecutive business days ending April 29, 2026.
The company has 180 calendar days, until October 27, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive business days. If it qualifies, Hoth may receive an additional 180-day grace period and could appeal any delisting decision. The company plans to monitor its share price and may consider actions such as a reverse stock split to meet Nasdaq listing standards.
Hoth Therapeutics, Inc. is preparing to resume sales of its common stock under its existing At the Market Offering Agreement with H.C. Wainwright & Co., LLC. The company had previously suspended and terminated the prior prospectus supplement and related prospectus, but the underlying Sales Agreement remained in effect.
To restart these at-the-market offerings, Hoth will file a new prospectus supplement to its shelf registration statement on Form S-3 (File No. 333-291566), which was previously declared effective by the SEC on December 4, 2025. The filing also includes a legal opinion and consent from Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the securities to be sold under the Sales Agreement.
Hoth Therapeutics, Inc. is offering, on an at-the-market basis, common stock having an aggregate offering price of up to $1,555,000 through H.C. Wainwright & Co., LLC as sales agent under a Sales Agreement dated November 8, 2024.
Sales may occur on Nasdaq or other U.S. trading markets, in negotiated transactions or directly to the agent. The company will pay a 3.0% commission to the sales agent. The prospectus supplement cites 19,127,643 shares outstanding and a public float of approximately $21,176,693 based on March 11, 2026 pricing used for the float calculation.
Hoth Therapeutics, Inc. entered into a securities purchase agreement to sell 2,857,144 shares of common stock at $0.70 per share, raising approximately $2.0 million in a registered direct offering under its Form S-3 shelf.
In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,857,144 additional shares at $0.85 per share, exercisable six months after issuance for five years and subject to a 4.99% beneficial ownership cap, waivable up to 9.99% with 61 days’ notice. H.C. Wainwright & Co. acted as placement agent, earning cash fees and warrants to buy 142,857 shares at $0.875 per share. Hoth plans to use net proceeds for working capital and general corporate purposes and has suspended use of its existing at-the-market prospectus supplement, with no ATM sales until a new supplement is filed.
Hoth Therapeutics, Inc. is offering 2,857,144 shares of common stock at an offering price of $0.70 per share to several institutional investors pursuant to a securities purchase agreement dated April 1, 2026. The gross proceeds from the public portion of the offering are approximately $2.0 million, before placement agent fees and expenses.
The company is conducting a concurrent private placement of unregistered warrants to purchase up to 2,857,144 shares (one warrant per share sold) exercisable beginning six months from issuance for five years at an exercise price of $0.85 per share. Delivery of the shares is expected on or about April 2, 2026, subject to customary closing conditions.